Skip to main content
. 2021 Oct 14;12:729851. doi: 10.3389/fimmu.2021.729851

Figure 1.

Figure 1

Design and initial evaluation of bispecific antibodies combining CI-MPR ligands and mAbs blocking the endo/lysosomal filovirus GP:NPC1 interaction. (A) A hypothetical mechanism for delivery of NPC2- and IGF2-tagged bsAbs (bottom) but not parental mAbs (top) to sites of GPCL:NPC1 interaction in late endosomal/lysosomal (LE) compartments. (B) Schematic representations of a subset of the antibodies tested in this study. Top row: parental mAbs, NPC1 domain C (NPC1–C)-specific mAb-548 and viral glycoprotein receptor-binding site (RBS)-specific mAb MR72. Middle row: NPC2-tagged bsAbs. NPC2 was fused to the N–terminus of the light chain (LCN) of mAb-548 and MR72. Bottom row: IGF2-tagged bsAbs. IGF2 was fused to the N–terminus of the heavy chain (HCN) of mAb-548 and MR72. (C) Heat map showing neutralizing IC50 values against rVSV-EBOV GP for the antibody panel. For curves that did not cross the 50% threshold, IC50 values were considered >100 nM.